N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 1.85 NOK -2.63% Market Closed
Market Cap: 604.1m NOK

Intrinsic Value

The intrinsic value of one NYKD stock under the Base Case scenario is 3.88 NOK. Compared to the current market price of 1.85 NOK, Nykode Therapeutics ASA is Undervalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NYKD Intrinsic Value
3.88 NOK
Undervaluation 52%
Intrinsic Value
Price
N
Worst Case
Base Case
Best Case

Valuation History
Nykode Therapeutics ASA

What is Valuation History?
Compare NYKD to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about NYKD?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Nykode Therapeutics ASA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Nykode Therapeutics ASA

Current Assets 108.6m
Cash & Short-Term Investments 106.2m
Receivables 2.4m
Non-Current Assets 38m
PP&E 7.2m
Intangibles 72k
Other Non-Current Assets 30.8m
Efficiency

Free Cash Flow Analysis
Nykode Therapeutics ASA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Nykode Therapeutics ASA

Revenue
7.9m USD
Operating Expenses
-48.1m USD
Operating Income
-40.3m USD
Other Expenses
14.9m USD
Net Income
-25.3m USD
Fundamental Scores

NYKD Profitability Score
Profitability Due Diligence

Nykode Therapeutics ASA's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Low 3Y Average Gross Margin
Declining Net Margin
Low Gross Margin
19/100
Profitability
Score

Nykode Therapeutics ASA's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

NYKD Solvency Score
Solvency Due Diligence

Nykode Therapeutics ASA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Nykode Therapeutics ASA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 5.2 NOK with a low forecast of 1.82 NOK and a high forecast of 8.93 NOK.

Lowest
Price Target
1.82 NOK
2% Downside
Average
Price Target
5.2 NOK
181% Upside
Highest
Price Target
8.93 NOK
382% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for NYKD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one NYKD stock?

The intrinsic value of one NYKD stock under the Base Case scenario is 3.88 NOK.

Is NYKD stock undervalued or overvalued?

Compared to the current market price of 1.85 NOK, Nykode Therapeutics ASA is Undervalued by 52%.

Back to Top